Neuroendocrine Tumor Clinical Trials

Find Neuroendocrine Tumor Clinical Trials Near You

Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). The main questions it aims to answer are: Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions. Participants will: Provide retrospective clinical, pathological, and metabolic data from hospital records. Have survival and recurrence outcomes assessed through follow-up data review.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Locations
Other Locations
China
Qilu Hospital of Shandong University
RECRUITING
Jinan
Qilu Hospital of Shandong University
NOT_YET_RECRUITING
Jinan
Contact Information
Primary
Hanxiang Zhan, MD. PhD.
zhanhanxiang@hotmail.com
+86 18560085156
Backup
Changhao Gao, MMed
gaochanghao44@gmail.com
Time Frame
Start Date: 2025-08-31
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 600
Treatments
Early-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
Late-onset pancreatic neuroendocrine tumors group
This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers.
Sponsors
Leads: Qilu Hospital of Shandong University
Collaborators: China-Japan Friendship Hospital, The Affiliated Hospital of Qingdao University, Qianfoshan Hospital

This content was sourced from clinicaltrials.gov